February 11, 2020 / 5:53 PM / 13 days ago

BRIEF-Xspray Pharma Says Stability Studies With Co's Commercially Manufactured Hynap-Dasa Tablets Began On Feb 11

Feb 11 (Reuters) - XSpray Pharma AB (publ):

* STABILITY STUDIES WITH COMPANY’S COMMERCIALLY MANUFACTURED HYNAP-DASA TABLETS BEGAN ON FEBRUARY 11

* ABBREVIATED NEW DRUG APPLICATION PLANNED TO BE SUBMITTED TO FDA IN Q3 OF 2020

* EXPECT OFFICIAL APPROVAL OF PRODUCTION FACILITY IN MILAN FROM ITALIAN PHARMACEUTICAL AUTHORITY, AIFA, WITHIN NEXT FEW MONTHS

* PIVOTAL CLINICAL BIOEQUIVALENCE STUDIES IN HEALTHY VOLUNTEERS WILL BE INITIATED DURING SPRING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below